ProfileGDS5678 / 1433670_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 73% 73% 73% 72% 74% 74% 74% 76% 78% 73% 72% 74% 73% 74% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 14.7124373
GSM967853U87-EV human glioblastoma xenograft - Control 24.7024273
GSM967854U87-EV human glioblastoma xenograft - Control 34.6942673
GSM967855U87-EV human glioblastoma xenograft - Control 44.7359372
GSM967856U87-EV human glioblastoma xenograft - Control 54.832474
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 14.7202974
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 24.7683174
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 35.0398376
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 45.4520578
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 14.7754573
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 24.6034672
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 34.800774
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 44.7587973
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 54.762274